More Than 80% of Women With Early-Stage Triple-Negative Breast Cancer Experienced a Prolonged Event-Free Survival With Keytruda Plus Chemotherapy Regimen

Updated March 31st, 2022

More Than 80% of Women With Early-Stage Triple-Negative Breast Cancer Experienced a Prolonged Event-Free Survival With Keytruda Plus Chemotherapy Regimen

NOW
PLAYING
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
NOW
PLAYING
Actor Terry Crews & Wife Rebecca Celebrate 34 Years of Marriage
NOW
PLAYING
Introduction to Early-Stage Breast Cancer
NOW
PLAYING
FDA Approval of After-Surgery Therapy Olaparib 'A Real Milestone' For Breast Cancer
NOW
PLAYING
New Hope For Some Early-Stage Breast Cancer Patients: FDA Approves Targeted Therapy Drug Verzenio
NOW
PLAYING
Verzenio is Significant & Cuts the Risk of Cancer Coming Back in Some Women With Early Breast Cancer A First For CDK4/6 Inhibitors

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... breast cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider